Axsome settles Auvelity patent litigation with Teva
Axsome Therapeutics (AXSM) stock rallied 15% on news the company has settled patent litigation with Teva (TEVA) over a ...
manilatimes22h
Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr - bupropion HCl) Patent Litigation
The settlement agreement resolves all outstanding patent litigation relating to AUVELITY.
FiercePharma18h
Axsome shares jump as settlement will keep Teva's Auvelity generic off the market until 2038
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'
Axsome Therapeutics, Inc. (NASDAQ:AXSM) signed a settlement agreement with Teva Pharmaceuticals Inc (NYSE:TEVA). The ...
Zacks.com on MSN1h
Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains?
Axsome (AXSM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Axsome announces settlement agreement resolving AUVELITY patent litigation
Axsome Therapeutics (AXSM) announced that it has entered into a settlement agreement with Teva Pharmaceuticals (TEVA) resolving all patent ...
Shares in Biopharma Firm Axsome Surge Over 20% After Settling Teva Patent Dispute
Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...
Investing on MSN20h
Axsome Therapeutics stock rises on patent litigation settlement
Axsome's CEO, Herriot Tabuteau, MD, expressed pride in the company's commitment to improving patient outcomes and emphasized ...
Axsome Therapeutics Shares Rise After Agreement with Teva Pharmaceuticals Ends Litigation
Under the agreement, Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric exclusivity is granted for Auvelity, or on or after ...
BofA raises Axsome stock target on extended Auvelity exclusivity
BofA Securities analyst Jason Gerberry increased the price target for Axsome Therapeutics (NASDAQ:AXSM) shares to $167 from the previous $143, while reiterating a Buy rating on the stock. This aligns ...
Axsome settles patent litigation with Teva over AUVELITY
NEW YORK - Axsome Therapeutics, Inc. (NASDAQ:AXSM), a $5.1 billion market cap biopharmaceutical company with impressive 91% gross profit margins, has reached a settlement agreement with Teva ...